Introduction
MicroRNAs (miRNAs) are small noncoding RNAs which control expression of target genes by either inhibiting protein translation or directly targeting mRNA transcripts of target genes for degradation (1) . Each miRNA has a specific seed sequence 7-8 nucleotides long, which directly binds to complementary sequences in regulatory regions of target genes. These binding regions are often in the 3' UTR of target genes, but increasingly are being reported in other non-coding regions such as promoter or intronic regions (2) . The short length of the seed sequence facilitates the targeting of many transcripts by a single miRNA (3) . Some estimates suggest that 30% of all eukaryotic genes are regulated by miRNAs (4; 5) . miR-155, a miRNA widely reported to be involved in lymphoma, is also now emerging to have a role in the progression of solid cancers (6) . This review will focus on the microRNA miR-155, and its role in breast cancer. miRNAs were discovered in 1993 when the C.elegans lin-4 gene, which is transcribed but not translated, was found to regulate levels of LIN-14 protein (7; 8) . Since this discovery there have been over 500 miRNAs described, regulating a wide range of genes and cellular processes, although the total predicted number of unique miRNAs encoded by the human genome is estimated to be over 1000 (9) . Many of these miRNAs are organised as gene clusters and transcribed as multicistronic messagesfor example, the MIRH1 gene encodes 6 different miRNAs (10) . The transcription and processing of miRNAs has been well characterised, and is depicted in Figure 1 Dicer exonucleases into a ~22 nucleotide RNA duplex. One strand of the duplex becomes the mature miRNA and is usually the functional, regulatory unit (12; 13) while the other is designated miR* and is usually degraded. The mature miRNA is loaded into Argonaute proteins, forming the RNA Induced Silencing Complex (RISC). The mature miRNA may then bind to its target by partial complementarity of target gene mRNA and either inhibit translation or cause degradation of the mRNA.
The miR-155 host gene, BIC, was first described in 1989 and postulated to be involved in the progression of lymphoma (14) . In 2002, Lagos-Quintana et al identified miR-155 as a regulatory RNA (15) . Subsequently, studies have focussed on the roles of miR-155 in lymphoma (16) (17) (18) (19) , and also in viral infection, cardiovascular disease and solid cancers (6; 20-22) . miR-155 has over 400 predicted gene targets (23) and more than 100 confirmed bona fide targets . There is now an emerging role of miR-155 in breast cancer progression (20; 21; 24) which is the focus of this review.
Clinical Relevance of miR-155 in Breast Cancer
Studies show the expression level of miR-155 is upregulated in breast cancer with high levels of miR-155 associated with clinicopathological markers, tumour subtype and poor survival rates, summarised in Table 1 (21, (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . Of 29 miRNAs found to be dysregulated in breast cancer, the majority were downregulated, with only miR-155 and miR-21 significantly upregulated (25) . Expression levels of 15 of these dysregulated miRNAs independently predict the invasive potential of breast tissue samples (25) . A small microarray study of 8 fresh breast tumour samples found miR-155 was upregulated in the breast tumours compared to normal adjacent tissue (34) .
In a larger study, 62 breast carcinomas were analysed to determine miR-155 levels. These findings were further supported by two studies involving microarray analyses of FFPE breast cancer samples, which found that miR-155 expression was upregulated in metastases (28, 33) .
Since miR-155 is associated with poor prognosis and/or metastasis, a correlation of miR-155 levels with breast cancer clinicopathological markers would be expected.
Analysis of 93 breast cancers for both miRNA levels alongside mRNA levels, to classify tumour subtypes, showed miR-155 levels were significantly upregulated in basal-like tumours and in estrogen receptor negative (ER-) tumours (27) . The correlation with basal-like tumours has particular clinical relevance due to the poor prognosis of this tumour subtype.
Studies have investigated whether serum samples could be used to identify aberrant miRNA expression levels in breast cancer patients. In a small study of 21 patients Zhu et al. found that multiple miRNAs could be detected in sera and the miRNA levels correlated with the levels in tissue samples (29) . The expression of miR-155 was higher in the serum of PR+ breast cancer patients than in the serum of PR-patients (29) . Further studies confirmed these findings, with a significant correlation reporting contradictory results (27, 29) . The topic of serum miRNAs is also somewhat controversial, with some studies suggesting that serum miRNA levels are robust (35; 36) , and others claiming that the miRNAs often used as normalisation controls are highly variable in sera samples, and thus miRNA quantification in sera is not reproducible (37) . This suggests analysis of serum alone is not sufficient to determine whether miR-155 is differentially expressed. Since the number of samples in these studies is generally low, resolution requires a more robust study.
Taken together, these studies show miR-155 expression is upregulated in breast cancer, consistent with its status as an oncomiR, and is associated with more aggressive breast tumours. However, the relationships between miR-155 and clinicopathological markers, such as ER and PR status and tumour subtype, is inconsistent, probably due to small sample sizes and methodological aspects. For example, the upregulation of miR-155 expression in PR+ tumours was only identified in one study of a small number of samples (29) . Further studies are required to confirm, and elucidate the basis, of the relationship between miR-155 and hormone receptor status.
Functional characterisation of miR-155 oncogenic activities in breast cancer
An important step in determining the clinical significance of miR-155, is to determine whether high expression levels are causally related to the development of breast cancer. In vitro effects of altering miR-155 expression levels were assessed in a panel of breast cancer cell lines (21) . miR-155 expression was inhibited by anti-miR in HS578T cells. An anti-miR is a 2′-O-methyl oligoribonucleotide that inhibits the action of a miRNA. One proposed mechanism for anti-miR action is antisense binding 
to the mature miRNA positioned in the RISC (38) . The HS578T cell line expresses high levels of endogenous miR-155, and anti-miR-155 application resulted in cell cycle arrest and induction of apoptosis, implicating miR-155 in these processes (21) .
Conversely, ectopic overexpression of miR-155 in BT474 cells, which express very low levels of endogenous miR-155, promoted cell proliferation and survival and also improved chemoresistance (21) . Taken 
Target genes of miR-155
The function of microRNAs are limited to inhibition of their target mRNA and consequent effects on cellular processes. miR-155 clearly has a role in breast cancer, and understanding this role requires the identification of critical miR-155 target genes. 
Targetscan is an in silico prediction software commonly used to identify putative target genes of particular miRNAs by alignment of the 7 or 8 nucleotide seed sequence with the 3' UTR of 30,858 human transcripts based on conservation between human and mouse sequences (23) . Targetscan The large number of validated miR-155 targets presented in Supplementary Table 1 provide many avenues of further investigation as to the clinical potential of miR-155.
The further investigation of these targets will be required to confirm the mechanistic and regulatory actions of miR-155, and their contribution to breast cancer. 
